Leah Kuntz

Fluvoxamine was not intended as a COVID-19 medication, but a recent study suggests it may help prevent serious complications for patients with COVID-19.

Manufacturing issues stall progress with ALKS 3831, Alkermes’s promising new drug for the treatment of schizophrenia and bipolar I disorder.

New research underlies the need for addressing identity in young patients during early stages of psychosis.

A new prescription smartwatch app may improve sleep quality for those with nightmare disorders.

Recently published data suggests a promising new treatment for patients with obsessive-compulsive disorder.

Good news in the fight against Alzheimer disease, with major progress in new, innovative treatments.

Here are some statistics around suicide to help put things in perspective.

An explanation for the clinical presentation of delusions and hallucinations may have just been found.

A potential treatment for attention-deficit/hyperactivity disorder goes back to the drawing board.

Antipsychotic medications for young children are not being prescribed appropriately, according to a recent study.

Have you chatted recently with your patients about their social media use? This study shows how and why it is important.

A study in Spain uncovers the hard truth about gender inequality in mental health care.

A diagnosis of depression, anxiety disorders, or bulimia may also indicate a heightened risk of excessive drinking.

What treatments are there to assist in the rehabilitation of veterans?

Does race affect the risk of stroke in patients with depression? A new study finds some answers and some new questions.

A new, unique long-acting injectable for treating schizophrenia may be on the way.

A recent study found riluzole may effectively combat hyperarousal symptoms in combat veterans with PTSD.

Adial Pharmaceuticals announced the reactivated US Investigational application for their Alcohol Use Disorder therapeutic agent, AD04.

Akili announces new data on treatment EndeavorRx that reports real-world improvement for children with ADHD.

Carlos M. Grilo, PhD, explained symptoms, causes, and treatment for binge-eating disorder in his talk at The Annual Psychiatric Times® World CME Conference™.

Can algorithms improve how you practice? Dr Osser explained more in his speech at the Annual Psychiatric Times® World CME Conference™.

New research is being conducted on how psychedelic substances may change the future of mental health care. Dr Carlin explained more in her speech at the Annual Psychiatric Times® World CME Conference™.

Cannabis and cannabis-derived products are widely debated. Dr Gorelick covered the issues surrounding this substance. Read more for highlights.

Read about the new results from Sage’s clinical study of depression treatment, zuranolone.

Terrorism is a crime from which the families of the victims may never recover. A recent study examines the grieving process in depth.

Alkermes plc’s new drug, ALKS 3831, pending FDA approval, could be helpful in the treatment of patients with schizophrenia or bipolar I disorder.

The Annual Psychiatric Times® World CME Conference™ is going to be packed full of informative, must-see sessions. Check out this preview of the week's agenda.

World Mental Health Awareness Day is October 10. Here are some ideas for you to treat yourself while also supporting mental health.

Veterans with chronic pain should consider reducing alcohol usage to combat symptoms.

Financial distress in patients with ADHD greatly increases risk of suicide. Read more.